These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 15170189)
21. Overcoming the challenges in the pharma/biotech industry. Graul AI; Prous JR Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900 [TBL] [Abstract][Full Text] [Related]
23. Open channels: Do new cystic-fibrosis therapies hold the key to treating other genetic disorders? Groopman J New Yorker; 2009 May; ():30-4. PubMed ID: 19408414 [No Abstract] [Full Text] [Related]
25. The newest stage in the evolution of drug development. Ross JS Drug News Perspect; 2009; 22(1):59. PubMed ID: 19338121 [No Abstract] [Full Text] [Related]
26. Obstacles and opportunities in new drug development. Kaitin KI Clin Pharmacol Ther; 2008 Feb; 83(2):210-2. PubMed ID: 18202685 [No Abstract] [Full Text] [Related]
27. Pharma pursues novel models for academic collaboration. Hughes B Nat Rev Drug Discov; 2008 Aug; 7(8):631-2. PubMed ID: 18670424 [No Abstract] [Full Text] [Related]
28. Medical pharmaceuticals and distributive justice. Boylan M Camb Q Healthc Ethics; 2008; 17(1):30-44. PubMed ID: 18462543 [No Abstract] [Full Text] [Related]
29. The interface between publicly funded and industry-funded research in pediatric psychopharmacology: opportunities for integration and collaboration. Vitiello B; Heiligenstein JH; Riddle MA; Greenhill LL; Fegert JM Biol Psychiatry; 2004 Jul; 56(1):3-9. PubMed ID: 15219466 [TBL] [Abstract][Full Text] [Related]
30. [Reaction to 'Bitter and gilded pills: psychiatry in the light (or shadow) of the pharmaceutical industry' and to 'The importance of public-private cooperation. Comment on Vandereycken']. Buis WM Tijdschr Psychiatr; 2006; 48(6):500-1; author reply 501-3. PubMed ID: 16956013 [No Abstract] [Full Text] [Related]
31. Approaches to the synthesis of immunolides: selective immunomodulatory macrolides for cystic fibrosis. Fecik RA; Nguyen PL; Venkatraman L Curr Opin Drug Discov Devel; 2005 Nov; 8(6):741-7. PubMed ID: 16312149 [TBL] [Abstract][Full Text] [Related]
32. Clinical trials in India: balancing economic opportunity with the public health context. Dandona L Natl Med J India; 2006; 19(2):57-9. PubMed ID: 16756189 [No Abstract] [Full Text] [Related]
33. Take your partner by the hand.. Smaglik P Nature; 2005 Jun; 435(7046):1281. PubMed ID: 15997477 [No Abstract] [Full Text] [Related]
34. The NIH, research institutions and industry: working together on a shared goal. Omary MB Gastroenterology; 2007 May; 132(5):1647-50. PubMed ID: 17484859 [No Abstract] [Full Text] [Related]
35. The state of innovation in drug development. Kola I Clin Pharmacol Ther; 2008 Feb; 83(2):227-30. PubMed ID: 18202690 [TBL] [Abstract][Full Text] [Related]
36. Clinical research in China and India: a paradigm shift in drug development. Singh R Drug Discov Today; 2006 Aug; 11(15-16):675-6. PubMed ID: 16846793 [No Abstract] [Full Text] [Related]
37. Therapeutic success via targeted approaches and strategic partnerships with clinical laboratories. Miller GA IDrugs; 2007 Mar; 10(3):181-4. PubMed ID: 17351872 [TBL] [Abstract][Full Text] [Related]
38. Leaders worry that U.S. is losing edge on cancer clinical trials. Twombly R J Natl Cancer Inst; 2008 Sep; 100(17):1196-9. PubMed ID: 18728275 [No Abstract] [Full Text] [Related]
39. A failed attempt at collaboration. Garattini S; Bertele' V; Bertolini G BMJ; 2013 Sep; 347():f5354. PubMed ID: 24004996 [No Abstract] [Full Text] [Related]
40. Cystic fibrosis: hope remains for a 'miracle cure'. Dick M Biotechnol J; 2006 May; 1(5):502-3. PubMed ID: 17086624 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]